ARQT — Arcutis Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.65bn
- $1.56bn
- $196.54m
- 31
- 11
- 80
- 36
Annual cashflow statement for Arcutis Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -136 | -206 | -311 | -262 | -140 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 8.39 | 27.7 | 63 | 37.1 | 40.4 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 14.1 | 3.62 | -10.2 | -23.5 | -15.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -113 | -175 | -258 | -247 | -112 |
| Capital Expenditures | -0.321 | -0.995 | -23.3 | -0.428 | -5.14 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -182 | -75 | -63.9 | 181 | 34 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -182 | -76 | -87.2 | 180 | 28.8 |
| Financing Cash Flow Items | 0 | -1.64 | -2.19 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 298 | 282 | 302 | 101 | 66.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.29 | 31.4 | -43.1 | 34.4 | -17.4 |